Teladoc Health Form 4 / Stephany Verstraete ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Verstraete Stephany

(Last)

(First)

(Middle)

C/O TELADOC HEALTH, INC.,

2 MANHATTANVILLE ROAD, SUITE 203

(Street)

PURCHASE

10577

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
CHIEF MARKETING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/01/2024		M		4,437	A	⁽¹⁾	47,554	D
Common Stock	03/01/2024		M		437	A	⁽¹⁾	47,991	D
Common Stock	03/01/2024		M		867	A	⁽¹⁾	48,858	D
Common Stock	03/01/2024		M		1,404	A	⁽²⁾	50,262	D
Common Stock	03/01/2024		M		13,021	A	⁽²⁾	63,283	D
Common Stock	03/01/2024		M		1,148	A	⁽²⁾	64,431	D
Common Stock	03/04/2024		S		7,945⁽³⁾	D	$14.516	56,486	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Stock Units	⁽⁴⁾	03/01/2024		A		13,313⁽⁵⁾		⁽⁶⁾	⁽⁶⁾	Common Stock	13,313	$0	13,313	D
Performance Stock Units	⁽¹⁾	03/01/2024		M			4,437	⁽⁷⁾	⁽⁷⁾	Common Stock	4,437	$0	8,876	D
Performance Stock Units	⁽¹⁾	03/01/2024		M			437	⁽⁸⁾	⁽⁸⁾	Common Stock	437	$0	0	D
Performance Stock Units	⁽¹⁾	03/01/2024		M			867	⁽⁹⁾	⁽⁹⁾	Common Stock	867	$0	0	D
Restricted Stock Units	⁽²⁾	03/01/2024		M			1,404	⁽¹⁰⁾	⁽¹⁰⁾	Common Stock	1,404	$0	5,616	D
Restricted Stock Units	⁽²⁾	03/01/2024		M			13,021	⁽¹¹⁾	⁽¹¹⁾	Common Stock	13,021	$0	26,042	D
Restricted Stock Units	⁽²⁾	03/01/2024		M			1,148	⁽¹²⁾	⁽¹²⁾	Common Stock	1,148	$0	0	D

Explanation of Responses:

1. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.

2. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

3. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.

4. Each performance stock unit represents a contingent right to receive one share of TDOC common stock.

5. Performance award amount determined based on metrics in respect of the issuer's 2023 financial results.

6. The performance stock units vest as to one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

7. On March 1, 2024, the reporting person earned 13,313 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

8. On March 2, 2023, the reporting person earned 874 performance stock units, vesting in two substantially equal annual installments beginning on March 2, 2023.

9. On March 2, 2022, the reporting person earned 2,602 performance stock units, vesting in three substantially equal annual installments beginning on March 2, 2022.

10. On March 1, 2022, the reporting person was granted 16,844 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

11. On March 3, 2023, the reporting person was granted 39,063 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

12. On March 2, 2021, the reporting person was granted 3,442 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	03/05/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Teladoc Health (TDOC) Form 4Teladoc Health / Stephany Verstraete ownership change